News
Leerink upgrades Eli Lilly following landmark deal with U.S.
Published
5 months agoon
By
admin
Multiple waves of obesity treatment adoption should drive Eli Lilly higher from here, according to Leerink Partners. The investment firm upgraded the biopharmaceutical stock to outperform from market perform. Analyst David Risinger also hiked his price target to $1,104 per share from $886, pointing to upside of 19% from Friday’s close. Eli Lilly reached deal with the Trump administration in which Medicare will begin covering GLP-1s for certain patients with obesity beginning next year. Monthly out-of-pocket costs for patients could range anywhere from $50 to $350. LLY YTD mountain LLY YTD chart “LLY’s deal with the U.S. government should significantly enhance obesity drug adoption prospects and more than offset lower pricing. LLY estimates that the Medicare agreement will add 40M U.S. potential candidates for obesity treatment, which represents over 4x LLY’s estimate of the current 8.5M U.S. patients on obesity Rx treatment today,” the analyst wrote. “We expect LLY to succeed in the price for volume game, given its tremendous scale advantages and growing obesity portfolio.” The analyst also expects three new drugs to strengthen Eli Lilly’s leadership position and act as growth drivers ahead — orforglipron, retatrutide and eloralintide. In particular, Risinger expects the last of these three to be a “mega-blockbuster” drug. “We envision market positioning as follows: orforglipron for overweight and modestly obese patients plus as a global low-cost therapy for T2D, tirzepatide as the ‘workhorse’ for obese patients, retatrutide for more severely obese patients or those who fail tirzepatide, and eloralintide for patients who cannot tolerate GLP-1s or want an off-ramp,” he wrote. “Ex-U.S. countries provide greater coverage for LLY therapies in the future.” Eli Lilly stock has popped 20% this year.
This industrial giant is emerging as a big AI play, says Wells Fargo
Novo Nordisk’s strategy tested as investors push back on board revamp
Alibaba plans AI subscriptions, stablecoin-like payments with JPMorgan
UK borrowing costs spike on report government to scrap plans to raise income tax
Trump’s threatened the BBC with a $1B lawsuit: Here’s what’s going on
UBS’s picks for global returns next year
Wells Fargo sees Caterpillar continuing to roar higher, emerging as an artificial intelligence play. The bank initiated shares of...
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic...
Key Points Alibaba plans to use “tokenization” of payments for cross-border transactions in its business-to-business arm. Kuo Zhang, president...
Rachel Reeves, U.K. chancellor of the exchequer, delivers a speech in London, UK, on Tuesday, Nov. 4, 2025. Bloomberg...
US President Donald Trump speaks to reporters as he arrives at Palm Beach International Airport on Oct. 31,...
Investors looking for global diversification opportunities should look to a specific subset of stocks in Europe, according to UBS...
Eakarat Buanoi | Istock | Getty Images LISBON, Portugal — Top tech executives told CNBC they’re concerned about...
Tan Su Shan, deputy chief executive officer and managing director of institutional banking at DBS Group Holdings Ltd., speaks during...
CHENGDU, CHINA – OCTOBER 18: People walk past the Louis Vuitton store at Taikoo Li, a high-end shopping area that...
The United States said Thursday it will remove tariffs on some foods and other imports from Argentina, Ecuador, Guatemala and...
